Breast Cancer Trial, Recruiting NCT04878666 Sponsor: University Hospital Tuebingen Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT04878666
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with breast cancer that has come back (recurred) in the same area, confirmed by a tissue sample (biopsy), where surgery either left very little margin (1mm or less), did not fully remove the cancer, or where the recurrence cannot be surgically removed at all
  • People aged 18 or older
  • People who are reasonably well and able to carry out daily activities (this is measured using a standard scale called ECOG, scores 0–2 — confirm with trial site what this means for a specific situation)
  • People whose life expectancy is estimated to be more than 2 years
  • People who have given their written informed consent to participate

Who may not be able to join:

  • People with widespread cancer that has spread to distant parts of the body, where life expectancy is estimated to be less than 2 years
  • People with serious heart conditions, including severe heart failure, coronary heart disease, a heart attack within the last 6 months, or a significant type of abnormal heart rhythm called AV block III° (confirm with trial site)
  • People who have a cardiac pacemaker
  • People who have or have had another type of cancer, unless it is certain types that are considered low-risk or have been successfully treated more than 5 years ago (such as early-stage cervical, skin, or bladder cancers — confirm with trial site for specific cases)
  • People who are pregnant or breastfeeding
  • People who have an implanted port (a small medical device used to deliver medication) on the same side of the body that would be treated
  • People who have had a blood clot in the subclavian vein (a large vein near the shoulder) within the last 6 months
  • People whose circumstances make it not possible to safely receive the hyperthermia (heat-based) treatment used in this trial (confirm with trial site)
  • People who would not be able to attend regular follow-up appointments as required by the trial
  • People who have had an organ transplant
  • People who have other implanted devices or materials in the chest wall on the same side as the area to be treated

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vanessa Heinrich, MD, University Hospital Tübingen

Phone: +49 (0) 7071 29-

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital Tuebingen
Registry
ClinicalTrials.gov
Start date
1 August 2020
Est. completion
31 December 2021

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Evaluation of the health-related Quality of Life (QoL) during and after hyperthermic radiotherapy. QoL will be measured by the EORTC QLQ BR 23

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov